Asparaginase (Elspar)
This medication was discontinued by the manufacturer in December 2012, and is now essentially out of stock. Alternatives include Pegaspargase (Oncaspar) or Asparaginase Erwinia chrysanthemi (Erwinaze).
General information
Class/mechanism: Depletes plasma asparagine, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase.[1][2]
Route: IV, IM
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- B-cell acute lymphoblastic leukemia
- Extranodal NK/T-cell lymphoma, nasal type
- NK/T-cell lymphoma
- T-cell acute lymphoblastic leukemia
Patient drug information
- Asparaginase (Elspar) patient drug information (Chemocare)[3]
- Asparaginase (Elspar) patient drug information (UpToDate)[4]
Also known as
- Generic names: colaspase, crisantaspase, L Asparaginase, L-ASP
- Brand names: Asparaginasa, Chephacardin, Crasnitin, Elspar, Engenase, Kidrolase, Laspar, L Asparaginasa, L Asparaginasum, L-Asperone, L-Ginase, Leucoginase, Leunase, Onconase, Paronal
References
- Drug index
- Chemotherapy
- Intravenous medications
- Intramuscular medications
- Subcutaneous medications
- Neutral chemotherapy
- Enzymes
- B-cell acute lymphoblastic leukemia medications
- Extranodal NK/T-cell lymphoma, nasal type medications
- NK/T-cell lymphoma medications
- T-cell acute lymphoblastic leukemia medications
- Drugs FDA approved in 1978
- Discontinued
- WHO Essential Cancer Medicine